Bespoke Drug Discovery Service

StemTech scientists are experts in producing human cell models of neurological disorders. We have efficient and unique protocols that generate a range of relevant cell types including:

  • Cortical forebrain excitatory neurons
  • Cortical inhibitory interneurons
  • Astrocytes
  • Microglia
  • Macrophages
  • Non-peptidergic nociceptors
  • Peptidergic nociceptors

We can work with blood or skin samples from patients and subjects you may have recruited to your own research study or we also have access to a range of neurological patient iPSC lines.

  • We can use these models for drug target discovery and target validation.
  • We can evaluate the effect of a screening hit, a lead molecule or a clinical candidate in human physiological and/or disease models.
  • We can partner with you to develop precision medicines, for example complementing clinical trials with in vitro iPSC model trials to identify patient subgroups likely to respond to therapy.
  • Combined with our fast, large scale, high quality iPSC reprogramming service – we can undertake parallel in vitro trials on 100s of patients in a few months.

Stem Cells for Drug Discovery

Drug discovery has traditionally relied upon cell lines from animals or tumours but this is now considered a major reason for why compounds investigated in pre-clinical studies fail to become effective medicines in clinic. These traditional cell lines do not accurately reflect some of the workings of cells and processes in the human body.

Human induced pluripotent stem cells have therefore become an important tool for drug discovery, through the ‘capture’ of the genetic backgrounds of the patients adult cells that are retained in the iPSCs. By turning iPSC into specialised adult cells, disease processes can then be examined on human cell types relevant to the disease.

Once iPSC lines from patients or healthy controls are generated, the difference between cells can be examined to identify disease phenotypes. The molecules that are responsible for these disease cellular phenotypes can also be discovered for drug target discovery and validation. Drug discovery can then proceed by screening compounds that reverse the disease cellular phenotype or by developing other assays to modulate novel drug targets.